Shin'etsu Region, Japan
Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
Pediatric participants will be enrolled as follows: - Cohort 1: Infants and children from 4 weeks postnatal age, weighing ≥ 1.5 kg to < 40 kg - Cohort 2: Neonates, either born at term or preterm, weighing ≥ 1.5 kg to < 6 kg
Phase
2Span
61 weeksSponsor
Gilead SciencesFukuoka
Recruiting
Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)
JDEPTH-LM Registry is a prospective observational multi-center study. The investigators will enroll and treat patients in the registry who meet the selection criteria under usual care and for whom PCI with W-KBT following on crossover stenting for LMT-LAD direction, proximal optimization technique (POT), and conventional kissing balloon technique (C-KBT) is the optimal treatment. The operators shall obtain oral or written consent from patients who meet the criteria before performing PCI, indicating the intention to perform PCI with W-KBT, and shall keep records. The investigators will continuously register cases attempting PCI with W-KBT according to the protocol and evaluate its efficacy and safety using data from this multi-center registry.
Phase
N/ASpan
292 weeksSponsor
TCROSS Co., Ltd.Fukuoka
Recruiting
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
Phase
2Span
81 weeksSponsor
AbbVieFukuoka
Recruiting
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
This trial will evaluate the safety and efficacy of valemetostat tosylate (DS-3201b) in combination with fixed-dose pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic NSCLC without actionable genomic alterations, whose tumor has PD-L1 TPS ≥50%, and who have not received prior systemic therapy for advanced or metastatic NSCLC. The trial will be in 2 phases, dose escalation and dose expansion phases.
Phase
1/2Span
287 weeksSponsor
Daiichi SankyoFukuoka
Recruiting
Focused Research On Neurofeedback Therapy In Eradicating Depression (FRONTIER)
Phase
1/2Span
71 weeksSponsor
UNB Sumiyoshi Jinja Mae ClinicFukuoka
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
Phase
3Span
172 weeksSponsor
argenxFukuoka
Recruiting
Fukuoka
Recruiting
Software as a Medical Device for the Treatment of Patients With PTSD
Phase
2/3Span
179 weeksSponsor
Otsuka Medical Devices Co., Ltd. JapanFukuoka
Recruiting
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Phase
3Span
455 weeksSponsor
CelgeneFukuoka
Recruiting
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Phase
3Span
265 weeksSponsor
Eli Lilly and CompanyFukuoka
Recruiting